Denial,Thanks for your kind words.Yes I did attend Chris's...

Denial,

Thanks for your kind words.

Yes I did attend Chris's session and yes it was just one of the amazing sessions.

How did you get those quotes? Are they on social media for example?

Oh Denial wouldn't it be great if PAR had started some work already in this area in the background to really KICK up the future potential of this out of this world drug???







PAR are WAY AHEAD of the game....they have already done a Phase 1 on HFpEF - Heart Failure! Half the world's heart failure CANNOT BE CURED/ADDRESSED with ANY drugs out in the market, only iPPS has shown an addressing of this indication.









(Below From PAR's website)

Heart failure (HF) is a major emerging public health problem associated with increasing prevalence in the ageing population, high morbidity and mortality rates, and the challenges involved with patient management and healthcare costs.

The number of patients with heart failure worldwide increased from 33.5 million in 1990 to 64.3 million in 2017 and this number is projected to increase in the next decade. Common risk factors that predispose individuals to heart failure include age (>65 years), coronary artery disease, a history of myocardial infarction, hypertension, obesity, smoking and diabetes.Heart failure is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality that results in reduced cardiac output and/or elevated intracardiac pressures.

There are two distinct subpopulations of HF classified based on the pumping function measured by echocardiography called HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), respectively. HFrEF and HFpEF are distinguished further by different disease mechanisms, co-morbidities and responses to treatment. 3,4 The prevalence estimates for HFpEF lies in the range from 1 to 3 %, and is anticipated to increase.

HFpEF is associated with high mortality rates of 20-29 % annually, and 53-74 % in a 5-year period. Due to the increase in prevalence and limited options for therapy, there is an urgent need for novel and improved treatment strategies for HFpEF patients.Inflammation, tissue damage and/or adverse tissue remodeling are the biological processes that lead to the development of chronic heart failure.

In HF, extracellular matrix degrading enzymes present in myocardial tissues such as ADAMTS-4 cause adverse tissue remodelling; as well as inflammation and vascular endothelial cell activation which affect cardiac function.




REFS:
https://app.sharelinktechnologies.com/announcement/asx/2f3b2b340dae93c54889c174e009b420
https://paradigmbiopharma.com/product-development/hf/